MRC1 and cancer: The median PFS in women with a PFI of ≥ 12 months who were re-administered platinum-based therapy in the SGSG-012/GOTIC-004 Intergroup study was 10.3 months, which was likely equivalent to or even better than that afforded by LEN/PEM [among those with cancers deficient in the MMR protein (dMMR): 10.7 months, among those having cancers with intact MMR protein expression (MMR proficient, pMMR): 6.6 months] [4, 6].